Company: DMAC
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001437749-25-009696
Chunk: 25

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 25
---
 policy governing the purchase, sale, and/or other dispositions of our securities by directors, officers and employees, among other insiders. We believe our insider trading policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and the Listing Rules of the Nasdaq Stock Market. Our insider trading policy is filed with the SEC as an exhibit to our Annual Report on Form 10-K for the year ended December 31, 2024.

<div align='center'>22

CORPORATE GOVERNANCE</div>

Management by Board of Directors

The Board of Directors is responsible for overseeing the management of DiaMedica and for the conduct of our affairs generally. Each director is elected annually by the shareholders and serves for a term that will end at the next annual general meeting of shareholders.

The Board of Directors facilitates its exercise of independent supervision over the management of DiaMedica through a combination of formal meetings of the Board of Directors and informal discussions amongst Board members. The Board of Directors is comprised of a majority of independent directors. The Board of Directors manages governance matters both directly and through its Board committees, which are described in more detail below. The Board of Directors looks to management of DiaMedica to keep it apprised of all significant developments affecting DiaMedica and our operations. All major acquisitions, dispositions, investments, contracts and other significant matters outside the ordinary course of our business are subject to approval by the Board of Directors.

Corporate Governance Guidelines

The Board of Directors has established Corporate Governance Guidelines that describe our basic approach to corporate governance. Among the topics addressed in our Corporate Governance Guidelines are:

| ●    Board size and qualifications                     | ●    Conflicts of interest                           |
| ●    Selection of new directors                        | ●    Director independence                           |
| ●    Board leadership                                  | ●    Board interaction with corporate constituencies |
| ●    Board committees                                  | ●    Change of principal occupation                  |
| ●    Director responsibilities                         | ●    Term limits                                     |
| ●    Board and committee meetings                      | ●    Retirement and resignation policy               |
| ●    Executive sessions of independent directors       | ●    Board compensation                              |
| ●    Meeting attendance by directors and non-directors | ●    Stock ownership by directors                    |
| ●    Appropriate information and access                | ●    Board compensation                              |
| ●    Ability to retain advisors                        | ●    Board access to senior management               |
| ●    CEO evaluation                                    | ●    Management development                          |
| ●    Succession planning                               | ●    Loans